Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Tony Gutschner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1722-3134; OpenAlex author ID A5063332455. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 9

  1. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  2. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  3. FOXM1 regulates platelet-induced anoikis resistance in pancreatic cancer cells. Co-author DOI 10.1186/s12964-025-02644-8↗
  4. Multi-level Analysis of Codon Usage Patterns Reveals Systematic Optimization of Oncogenic Gene Expression in Pancreatic Cancer Last author DOI 10.64898/2026.04.24.720399↗
  5. Long Non-Coding RNAs and RNA-Binding Proteins in Pancreatic Cancer Development and Progression. Last author DOI 10.3390/cancers17101601↗
  6. LINC00261 Is Differentially Expressed in Pancreatic Cancer Subtypes and Regulates a Pro-Epithelial Cell Identity. Co-author DOI 10.3390/cancers12051227↗
  7. Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. Last author DOI 10.3390/cancers12082077↗
  8. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  9. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Monika Hämmerle · 4 shared papers, 2020–2026 · strength 0.96
  2. Stefan Hüttelmaier · 4 shared papers, 2020–2026 · strength 0.90
  3. Markus Glaß · 3 shared papers, 2020–2026 · strength 0.63
  4. Pit Preckwinkel · 2 shared papers, 2025–2026 · strength 0.62
  5. Andrea Viale · 4 shared papers, 2017–2026 · strength 0.49
  6. Huamin Wang · 4 shared papers, 2017–2026 · strength 0.49
  7. Giannicola Genovese · 4 shared papers, 2017–2026 · strength 0.49
  8. Haoqiang Ying · 4 shared papers, 2017–2026 · strength 0.49
  9. Ronald Anthony Depinho · 4 shared papers, 2017–2026 · strength 0.49
  10. Jason B. Fleming · 4 shared papers, 2017–2026 · strength 0.49
  11. Prasenjit Dey · 4 shared papers, 2017–2026 · strength 0.49
  12. Anirban Maitra · 4 shared papers, 2017–2026 · strength 0.49
  13. Giulio Francesco Draetta · 4 shared papers, 2017–2026 · strength 0.49
  14. Lisa Mueller · 1 shared paper, 2026 · strength 0.36
  15. Alissa Ernesti-Soldatkin · 1 shared paper, 2026 · strength 0.33
  16. Ágnes Dorn · 2 shared papers, 2020 · strength 0.27
  17. Lifeng Yang · 2 shared papers, 2017–2026 · strength 0.26
  18. Di Zhao · 2 shared papers, 2017–2026 · strength 0.26
  19. Ya’an Kang · 2 shared papers, 2017–2026 · strength 0.26
  20. Deepak Nagrath · 2 shared papers, 2017–2026 · strength 0.26
  21. Alessandro Carugo · 2 shared papers, 2017–2026 · strength 0.23
  22. Virginia Giuliani · 2 shared papers, 2017–2026 · strength 0.23
  23. Timothy Paul Heffernan · 2 shared papers, 2017–2026 · strength 0.23
  24. Marco Dal Molin · 2 shared papers, 2017–2026 · strength 0.23
  25. Laura DeLong Wood · 2 shared papers, 2017–2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.